Evidence map›Paper›PMID 42383068›Full record

ArticleClinical and translational radiation oncology2026

Radiotherapy quality assurance in the PRO-GLIO trial: results from a dummy run comparing experts across twelve institutions in two Scandinavian countries.

Liv Cathrine Heggebø, Taran Paulsen Hellebust, Thomas Henry, Lars Fredrik Fjæra, Andreas Ottestad, Hillevi Rylander, Maziar Hervani, Morten Egeberg Evensen, Magnus Gustafsson, Hanne Blakstad and 26 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Liv Cathrine HeggebøDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Taran Paulsen HellebustDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Thomas HenryDepartment of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
Lars Fredrik FjæraDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Andreas OttestadDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Hillevi RylanderThe Skandion Clinic, Uppsala, Sweden.
Maziar HervaniDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Morten Egeberg EvensenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Magnus GustafssonDepartment of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
Hanne BlakstadDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Mette SprautenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Henriette MagelssenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Janani MoorthyDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Karin M AnderssonThe Skandion Clinic, Uppsala, Sweden.
Christina Vallhagen DahlgrenThe Skandion Clinic, Uppsala, Sweden.
Dorota GoplenDepartment of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Jorunn BrekkeDepartment of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Tor-Christian Aase JohannessenDepartment of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
Tora S SolheimCancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Kirsten MarienhagenDepartment of Oncology, University Hospital of North Norway, Tromsø, Norway.
Per BergströmDepartment of Oncology, Northern Sweden University Hospital, Umea, Sweden.
Måns AgrupDepartment of Oncology, Linköping University Hospital, Linköping, Sweden.
Sara KinhultDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Sara AlknerDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Ludvig DahlDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Ingrid KristensenDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Michael GubanskiDepartment of Radiotherapy, Karolinska University Hospital, Stockholm, Sweden.
Mark ZupancicMedical Unit Head, Neck, Lung, and Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Michael StrandeusDepartment of Oncology, The Ryhov County Hospital, Jönköping, Sweden.
Ingela RaunertDepartment of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
Anna FlejmerThe Skandion Clinic, Uppsala, Sweden.
Frida JakobssonDepartment of Oncology, Örebro University Hospital, Örebro, Sweden.
Christina RambergDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Katja WerleniusDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Malin BlomstrandDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Petter BrandalDepartment of Oncology, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Target volume and organ of interest (OOI) contouring and treatment planning for Methods: Five experts established consensus delineations for target volumes and defined OOI in two Results: Median dice similarity coefficient (DSC) for clinical target volume (CTV) was 0.92 for both cases, whereas the median 95th percentile Hausdorff distance for CTV was 0.54 cm and 0.65 cm. Larger variability in DSC and volume size was seen for OOI, e.g., a median DSC of 0.47 and 0.64 for the optic chiasm and between 0.61 and 0.77 for the hippocampi. DSC-derived DLS-values were within the range of manual delineations for all OOI. Conclusions: Delineation variation between study centers was minor for target volumes, especially for DSC of CTV. Variability was considerably higher for several OOI, representing a potential hazard not least with new and more precise radiotherapy techniques. Interestingly, DLS performed OOI-segmentation within the range of manual experts and represents a reasonable OOI-segmentation alternative in the future.

Indexed as

Deep learning segmentationIDH-mutated gliomaInterobserver variabilityQuality assurance

Identifiers

PMID42383068
PMCPMC13316294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.